In order to diagnosis a disease, such as cancer, a biopsy is frequently taken. However, the procedure is invasive and can be a painful or life-threatening experience. If a disease requires monitoring for progression, an invasive biopsy is also a less-than-ideal option, leading to a need for non-invasive alternatives.
Aiming to provide a solution to this limitation, Exosome Diagnostics is advancing non-invasive diagnostic tests based on exosomes, which are microvesicles found in blood, urine and cerebrospinal fluid (CSF). Exosomes are shed by cells under both normal and diseased conditions, and high-quality RNA and DNA can be extracted and purified for subsequent analysis, such as measuring levels of genes responsible for cancer or other diseases. The non-invasive nature of the approach also allows data to be collected in real time.
The company recently formed two partnerships involving this technology in the past few months, involving Mount Sinai and QIAGEN, respectively. Under the partnership with Mount Sinai, Exosome and the hospital will establish targeted research and biomarker discovery programs in oncology, inflammation and other disease areas. Exosome anticipates pursuing commercial development and FDA review of successful validations for in vitro diagnostics.
Under the partnership with QIAGEN, the two companies will develop and commercialize high-performance, co-branded kit products for the capture and processing of RNA and DNA from biofluid exosomes and other microvesicles. Initial product launches are anticipated the first half of 2014.
Read more about Exosome’s partnerships in the news releases below.